Market Overview

JP Morgan Says Jazz Pharmaceuticals Positioned For 'Organic Growth And Acquisition'

Share:
Related JAZZ
Vetr And Evercore Put Jazz Pharmaceuticals At Buy
Benzinga's Top Upgrades, Downgrades For February 23, 2017
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2016 Update (Seeking Alpha)

Shares of Jazz Pharmaceuticals (NASDAQ: JAZZ) are up almost 20 percent over the past five trading sessions.

JP Morgan started coverage of the company with an Overweight rating and $190 price target.

"In the context of an ongoing wave of consolidation in the specialty pharmaceuticals sector, we see Jazz as well positioned from both an organic growth and acquisition standpoint," writes analyst Jessica Fye.

Related Link: Leerink Says Tekmir Is 'Uniquely Positioned'

JP Morgan further comments that the company is diversifying away from from its core asset with acquisitions. The company has a borrowing allowance of $3 billion.

On Tuesday, Dow Jones reported Allergan (NYSE: AGN) is interested in purchasing Salix Pharmaceuticals (NASDAQ: SLXP), a competitor in the acquisition space. This news moved Jazz almost four percent higher to $158.14.

Latest Ratings for JAZZ

DateFirmActionFromTo
Feb 2017Evercore ISI GroupInitiates Coverage OnBuy
Dec 2016Cantor FitzgeraldInitiates Coverage OnOverweight
Aug 2016Janney CapitalInitiates Coverage onNeutral

View More Analyst Ratings for JAZZ
View the Latest Analyst Ratings

Posted-In: Jessica Fye JP MorganAnalyst Color Price Target Initiation Analyst Ratings

 

Related Articles (JAZZ + AGN)

View Comments and Join the Discussion!